Neurobiology of rhIGF-I: Rationale for Use in Motor Neuron Disease

  • J. L. Vaught
  • P. C. Contreras
  • M. Miller
  • N. Neff


Recombinant human insulin-like growth factor I (rhIGF-I) is a 70 aminoacid protein with a molecular weight of approximately 7.6 kilodaltons. It was originally identified and isolated based on endocrine and metabolic similarities it shared with insulin, particularly those related to the control of blood sugar. However, intense research has demonstrated that IGF-I is mechanistically, biochemically, and pharmacologically distinct from insulin.


Amyotrophic Lateral Sclerosis Motor Neuron Sciatic Nerve Grip Strength Motor Neuron Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hansson H-A, Rozell B, Skottner A (1987) Rapid axoplasmic transport of insulin-like growth factor I in the sciatic nerve of adult rats. Cell Tissue Res 247: 214–247CrossRefGoogle Scholar
  2. 2.
    Sara VR, Hall K, Von Holtz H, Humbel RE, Sjogren B, Wetterberg L (1982) Evidence of the presence of specific receptors for insulin-like growth factors 1 (IGF-1) and 2 (IGF-2) and insulin throughout the adult human brain. Neurosci Lett 34: 38–44Google Scholar
  3. 3.
    Baskin DG, Wilcox BJ, Figlewicz DP, Dorsa DM (1988) Insulin and insulin-like growth factors in the CNS. Trends Neurosci 11: 107–111PubMedCrossRefGoogle Scholar
  4. 4.
    Baron-Van Evercoon B-A, Olichon-Berthe C, Kowalski A, Visciano G, Van Obberghen E (1991) Expression of IGF-I and insulin receptor genes in the rat central nervous system: a developmental, regional, and cellular analysis. J Neurosci Res 28: 244–253Google Scholar
  5. 5.
    Kar S, Chabot J-G, Quirion R (1993) Quantitative autoradiographic localisation of [125I]insulin-like growth factor I, [125I]insulin-like growth factor II, and [125I]insulin receptor binding sites in developing and adult rat brain. Comp Neurol 333: 375–397Google Scholar
  6. 6.
    Neff NT, Prevette D, Houenou LJ, et al (1993) Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol 24: 1578–1588PubMedCrossRefGoogle Scholar
  7. 7.
    Henderson CE, Huchet M, Changeux JP (1983) Denervation increases a neurite promoting activity in extracts of skeletal muscle. Nature 302: 609–611PubMedCrossRefGoogle Scholar
  8. 8.
    Oppenheim RW (1991) Cell death during development of the nervous system. Annu Rev Neurosci 14: 453–501PubMedCrossRefGoogle Scholar
  9. 9.
    Hughes RA, Sendtner M, Thoenen H (1993) Members of several gene families influence survival or rat motoneurons in vitro and in vivo. J Neurosci Res 36: 663–671PubMedCrossRefGoogle Scholar
  10. 10.
    Li LX, Oppenheim RW, Lei M, Houenou LJ (1994) Neurotrophic agents prevent motor neuron death following sciatic nerve section in the neonatal mouse. J Neurobiol 25: 759–766PubMedCrossRefGoogle Scholar
  11. 11.
    Gruner JA, Wagner L, Bhat RV, Contreras PC, Miller MS (1997) rhIGF-I promotes motoneuron survival following neonatal sciatic transection. 27th Annual Meeting, Society for Neuroscience, October 25–30,1997, New Orleans, A248. 19Google Scholar
  12. 12.
    Bjornskov EK, Norris FH Jr, Mower-Kuby J (1984) Quantitative axon terminal and end-plate morphology in amyotrophic lateral sclerosis. Arch Neurol 41: 527–530PubMedCrossRefGoogle Scholar
  13. 13.
    Dengler R, Konstanzer A, Kuther G, Hesse S, Wolf W, Struppler A (1990) Amyotrophic lateral sclerosis: Macro-EMG and twitch forces of single motor units. Muscle Nerve 13: 545–550Google Scholar
  14. 14.
    Caroni P, Grandes P (1990) Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors. J Cell Biol 110: 1037–1317CrossRefGoogle Scholar
  15. 15.
    Caroni P (1993) Activity-sensitive signals by muscle-derived insulin-like growth factors in the developing and regenerating neuromuscular system. Ann N Y Acad Sci 692: 209–222PubMedCrossRefGoogle Scholar
  16. 16.
    Lewis ME, Neff NT, Contreras PC, et al (1993) Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 124: 73–88PubMedCrossRefGoogle Scholar
  17. 17.
    Contreras PC, Steffier C, Yu E, Callison K, Stong D, Vaught J (1995) Systemic administration of rhIGF-I enhanced regeneration after sciatic nerve crush in mice. J Pharmacol Exp Therap 274: 1443–1499Google Scholar
  18. 18.
    Hantai D, Akaabourne M, Lagord C, et al (1995) Beneficial effects of insulin-like growth factor-I on Wobbler mouse motoneuron disease. J Neurol Sci 129: 122–126PubMedCrossRefGoogle Scholar
  19. 19.
    Vergani L, Finco C, Di Giulio AM, Müller EE, Gorio A (1997) Effects of low doses of glycosaminoglycans and insulin-like growth factor-I on motor neuron disease in wobbler mouse. Neurosci Lett 228: 41–44PubMedCrossRefGoogle Scholar
  20. 20.
    Gorio A, Vergani L, Losa M, Pezzoni G, Calvano L, Finco C, Di Giulio AM, Torsello A, Mtiller EE (1998) IGF-I and glycosaminoglycans improve peripheral nerve regeneration and motor neuron survival in models of motor neuron disease. In: Müller EE (ed) IGFs in the Nervous System. Springer-Verlag, Berlin Heidelberg New York, pp 84–85Google Scholar
  21. 21.
    Rothstein JD, Martin LJ, Kuncl RW (1992) Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 326: 1464–1468PubMedCrossRefGoogle Scholar
  22. 22.
    Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW (1993) Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 90: 6591–6595PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1998

Authors and Affiliations

  • J. L. Vaught
    • 1
  • P. C. Contreras
    • 1
  • M. Miller
    • 1
  • N. Neff
    • 1
  1. 1.Cephalon Inc.West ChesterUSA

Personalised recommendations